Immucell Corp /de/ (ICCC) · Oct 13, 2026 · Earnings
Sales update — Q3 sales $8.0M, up 46% year over year
ImmuCell’s Q3 earnings update shows 46% sales growth, better manufacturing and broad product gains—but the comparison benefits from weak prior-year sales.
ImmuCell is shifting resources from the discontinued Re-Tain program into its First Defense calf-health franchise, while expanding sales coverage and manufacturing capacity to meet demand. The company’s June 2026 capacity plan called for a roughly $3.5 million freeze-drying expansion followed by about $4.5 million of additional liquid-processing investment, showing that supply reliability—not just customer demand—remains central to the story.
The sales acceleration is real, but the 46% headline overstates the clean underlying comparison. Preliminary third-quarter product sales reached $8.0 million, up 46.0% from the prior-year quarter. Management explicitly says the comparison benefited from depressed third-quarter 2025 sales after unusually heavy distributor purchases in the second quarter of 2025. That makes the result less of a pure demand surprise than the headline suggests, although domestic sales still rose 29.2%, a healthier measure of underlying commercial momentum.
| Metric | Q3 2026 / nine months 2026 | Comparison |
|---|---|---|
| Total Q3 product sales | $8.0M | +46.0% year over year (Preliminary sales results) |
| Domestic Q3 sales | $6.9M | +29.2% year over year (Preliminary sales results) |
| Nine-month product sales | $25.6M | +27.8% year over year (Preliminary sales results) |
| Tri-Shield product sales | — | +51% year over year (Management discussion) |
| Dual-Force product sales | — | +36% year over year (Management discussion) |
| Functional feed line sales | — | +37% year over year (Management discussion) |
The better news is the breadth and execution behind the growth. Management says sales expanded across Tri-Shield, Dual-Force and the newer functional-feed line, while attributing the quarter to a larger sales team, improved commercial execution and more reliable manufacturing. That supports the broader recovery story: ImmuCell appears to be converting restored product availability into sales rather than relying on one product or one distributor order.
The filing improves the operating story but says nothing yet about profitability or cash conversion. This is a preliminary sales release, so it does not disclose gross margin, earnings, cash flow, inventory, backlog or the cost of the capacity buildout. The November reporting event matters because the sales increase must ultimately translate into healthy margins while the company funds a multiyear manufacturing expansion.
The company is ending its early-sales-reporting practice, making this the last standalone sales snapshot. Future updates will arrive with full quarterly financial metrics and market and distribution information, which should make the business easier to evaluate but removes the earlier revenue-only read-through between formal results.
Bottom line: This is a mildly positive update: demand and execution are improving across the portfolio, but the 46% increase is helped by a weak comparison and still needs confirmation through margins and cash flow. The event advances the First Defense growth-and-capacity story without fully proving its economics yet.
Q3 financial results call, November 13, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!